153 related articles for article (PubMed ID: 24969114)
21. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A
Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
[TBL] [Abstract][Full Text] [Related]
22. Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.
Sherlock M; Toogood AA; Steeds R
Heart; 2009 Apr; 95(7):522-3. PubMed ID: 19174419
[No Abstract] [Full Text] [Related]
23. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.
Kars M; Pereira AM; Bax JJ; Romijn JA
Eur J Endocrinol; 2008 Oct; 159(4):363-7. PubMed ID: 18703568
[TBL] [Abstract][Full Text] [Related]
24. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
25. Dopamine agonists and valvular heart disease.
Stephens JW; Price DE; Ionescu A
N Engl J Med; 2007 Apr; 356(16):1676; author reply 1678-80. PubMed ID: 17442913
[No Abstract] [Full Text] [Related]
26. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
Tan T; Cabrita IZ; Hensman D; Grogono J; Dhillo WS; Baynes KC; Eliahoo J; Meeran K; Robinson S; Nihoyannopoulos P; Martin NM
Clin Endocrinol (Oxf); 2010 Sep; 73(3):369-74. PubMed ID: 20550538
[TBL] [Abstract][Full Text] [Related]
27. Dopamine agonists and hyperprolactinaemia.
Martin NM; Tan T; Meeran K
BMJ; 2009 Mar; 338():b381. PubMed ID: 19258356
[No Abstract] [Full Text] [Related]
28. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.
Barake M; Evins AE; Stoeckel L; Pachas GN; Nachtigall LB; Miller KK; Biller BM; Tritos NA; Klibanski A
Pituitary; 2014 Apr; 17(2):150-6. PubMed ID: 23504371
[TBL] [Abstract][Full Text] [Related]
29. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
30. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
31. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.
Vallette S; Serri K; Rivera J; Santagata P; Delorme S; Garfield N; Kahtani N; Beauregard H; Aris-Jilwan N; Houde G; Serri O
Pituitary; 2009; 12(3):153-7. PubMed ID: 18594989
[TBL] [Abstract][Full Text] [Related]
32. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
[TBL] [Abstract][Full Text] [Related]
33. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
34. Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline.
Córdoba-Soriano JG; Lamas-Oliveira C; Hidalgo-Olivares VM; Tercero-Martínez A; Barambio-Ruíz M; Salas-Nieto J
Rev Esp Cardiol (Engl Ed); 2013 May; 66(5):410-2. PubMed ID: 24775830
[No Abstract] [Full Text] [Related]
35. Cabergoline and mitral regurgitation.
Delgrange E
N Engl J Med; 2006 Jan; 354(4):420; author reply 420. PubMed ID: 16436779
[No Abstract] [Full Text] [Related]
36. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.
Wakil A; Rigby AS; Clark AL; Kallvikbacka-Bennett A; Atkin SL
Eur J Endocrinol; 2008 Oct; 159(4):R11-4. PubMed ID: 18625690
[TBL] [Abstract][Full Text] [Related]
37. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Morikawa K; Nakayama T
Intern Med; 2011; 50(7):687-94. PubMed ID: 21467699
[TBL] [Abstract][Full Text] [Related]
38. Cabergoline use for pituitary tumors and valvular disorders.
Auriemma RS; Pivonello R; Ferreri L; Priscitelli P; Colao A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):89-97. PubMed ID: 25732645
[TBL] [Abstract][Full Text] [Related]
39. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
[TBL] [Abstract][Full Text] [Related]
40. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
Caputo C; Prior D; Inder WJ
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]